Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.
This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.
Johnson
Bankole A
BA
Department of Psychiatric Medicine, University of Virginia, Charlottesville 22908-0623, USA. bankolejohnson@virginia.edu
Mann
Karl
K
Willenbring
Mark L
ML
Litten
Raye Z
RZ
Swift
Robert M
RM
Lesch
Otto M
OM
Berglund
Mats
M
D000047:Academies and Institutes; D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000627:therapeutic use*; D000437:Alcoholism / Q000534:rehabilitation*; D000818:Animals; D003299:Cooperative Behavior; D003431:Cross-Cultural Comparison; D004221:Disulfiram / Q000627:therapeutic use; D017277:Drug Approval; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007400:Interprofessional Relations; D009271:Naltrexone / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D016032:Randomized Controlled Trials as Topic; D013654:Taurine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000427:Alcohol Deterrents; D015507:Drugs, Investigational; D013654:Taurine; D009271:Naltrexone; D000077443:Acamprosate; D004221:Disulfiram